LabVantage Appoints Bob Voelkner as Vice President, Sales and Marketing
News Nov 03, 2017
LabVantage Solutions promoted Robert T. Voelkner to Vice President, Sales and Marketing, to oversee business planning and sales strategies as well as all marketing initiatives. Mr. Voelkner had served as LabVantage’s Manager of Global Strategic Accounts and Sales Director since 2009.
“Bob brings 35 years of experience developing, marketing, and selling enterprise laboratory information management solutions to this expanded role,” said Dr. Ram Velidi, president of LabVantage. “He is considered an expert in applying commercial LIMS to laboratory types ranging from early discovery through quality production. His application and industry knowledge will be critical as we more tightly integrate marketing and sales.”
Joining the company’s executive leadership team, Mr. Voelkner will continue to develop and maintain business relationships with LabVantage’s global, world-class customers in a number of industries, including pharmaceutical, biopharmaceutical, clinical, food & beverage, and process chemicals. He will oversee marketing initiatives that emphasize LabVantage’s state-of-the-art technology, industry-specific solutions, and integrated services and support.
Prior to joining LabVantage in 2009, Mr. Voelkner was Americas Sales Manager for the LIMS division of Applied Biosystems. Previously, he spent seven years in a number of sales leadership positions at Thermo Fisher Scientific’s Informatics and Services division. He started his career at Beckman Coulter, Inc. as a senior software developer working on LIMS and chromatography data systems, progressing to Director of Global Sales and Marketing of its Laboratory Automation Operations division. He is a graduate of the University of Scranton with a bachelor’s degree in computer science.
A team of researchers has now created 3D maps of MT1 and MT2 melatonin receptors revealing the structural basis of the selectivity of each receptor subtype. They intend to use this structural information to design drug molecules that better target and bind to each of the two receptors.READ MORE